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Abstract
Background: Second generation antipsychotics (SGAs) are increasingly utilized in Bipolar Disorder (BD) but are
potentially associated with cognitive side effects. Also linked to cognitive deficits associated with SGA-treatment are
catechol-O-methyltransferase (COMT) gene variants. In this study, we examine the relationship between cognition in
SGA use and COMT rs5993883 in cohort sample of subjects with BD.
Methods: Interactions between SGA-treatment and COMT rs5993883 genotype on cognition was tested using
a battery of neuropsychological tests performed in cross-sectional study of 246 bipolar subjects.
Results: The mean age of our sample was 40.15 years and was comprised of 70 % female subjects. Significant
demographic differences included gender, hospitalizations, benzodiazepine/antidepressant use and BD-type diagnosis.
Linear regressions showed that the COMT rs5993883 GG genotype predicted lower verbal learning (p = 0.0006) and
memory (p = 0.0026) scores, and lower scores on a cognitive control task (p = 0.004) in SGA-treated subjects.
Interestingly, COMT GT- or TT-variants showed no intergroup cognitive differences. Further analysis revealed an
interaction between SGA-COMT GG-genotype for verbal learning (p = 0.028), verbal memory (p = 0.026) and
cognitive control (p = 0.0005).
Conclusions: This investigation contributes to previous work demonstrating links between cognition, SGA-treatment
and COMT rs5993883 in BD subjects. Our analysis shows significant associations between cognitive domains such as
verbal-cognition and cognitive control in SGA-treated subjects carrying the COMT rs5993883 GG-genotype. Prospective
studies are needed to evaluate the clinical significance of these findings.
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Background
Second generation Antipsychotics (SGAs) are distin-
guished from first generation antipsychotics by the ability
to control psychosis at doses associated with considerably
fewer extrapyramidal symptoms and a relatively greater 5-
HT2A/D2 binding affinity ratio [1]. This class of medica-
tion is increasingly utilized in the long-term treatment of
Bipolar Disorder (BD) as an alternative monotherapy or
more often as an adjunct treatment with lithium or anti-
convulsant agents. Significant underlying cognitive deficits
in BD patients have not only been observed in manic or
depressive episodes but also when euthymic, compared to
healthy controls [2–4]. Various medical or lifestyle factors
may influence cognitive functioning in this patient popula-
tion but the contribution of pharmacologic treatment to
deficits in cognition remains unclear. In schizophrenia,
evidence suggests that cognitive improvements after the
initiation of treatment have more to do with practice ef-
fects such as exposure, familiarity and/or procedural
learning than the implementation of second generation
antipsychotics [5]. However, there remains an abundance
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of recent findings to suggest there are cognitive effects
associated with SGA-treatment. Unlike the cognitive ben-
efits observed in some studies for SGA therapy in the
schizophrenia population [6–8], evidence indicates that
SGAs may have a further detrimental effect on cognition
in BD independent of other clinical factors [9, 10]. These
data highlight the need to investigate this issue in a large,
well-characterized sample of patients with BD.
Previous studies have shown that the regulation of dopa-
mine and dopamine receptors play a role in BD pathophysi-
ology and also in cognitive processes [11, 12]. Contributing
to dopamine signaling pathways are both environmental
and genetic factors. Catechol-O-methyltransferase (COMT)
is a major enzyme involved in dopamine metabolism in
the prefrontal cortex and has been associated with nu-
merous psychiatric phenotypes [13–15]. The COMT
Val108/158Met polymorphism (rs4680) and Val allele
load is associated with decreased cognitive perform-
ance, such as in executive functioning and working
memory in both schizophrenia and BD subjects [16–19].
Although not thoroughly characterized, other COMT
variants impacting cognition in BD subjects have been
described [16, 20]. The objective of this study was to
compare neuropsychological performance of SGA vs
non-SGA treated bipolar patients with different allelic
representation of the COMT variants. As previous as-
sociations link cognition deficits to treatment with
SGAs and COMT variant alleles in the BD population,
we hypothesize this COMT variant would result in




The Prechter Longitudinal Study of Bipolar Disorder is
an ongoing observational study of bipolar disorder at the
University of Michigan (HUM00000606) with the main
goal of gathering phenotypic data and biological material
[21]. The present study included 246 individuals from
this cohort with a DSM-IV diagnosis of BD (BD Type I
(n = 178), BD Type II (n = 39), BD not otherwise speci-
fied (NOS, n = 21), Schizoaffective disorder-bipolar type
(n = 8)). All subjects underwent an evaluation using the
Diagnostic Interview for Genetic Studies (DIGS; [22]),
neuropsychological testing, clinician questionnaires to
assess symptoms of depression and mania (Hamilton
Depression Rating-17 item (HDRS; [23]) and Young
Mania Rating Scale (YMRS; [24]). Diagnoses were con-
firmed using a best estimate process by at least three
MD/PhD clinicians. Medication groups were defined as
the use of an SGA at the time of cognitive testing. Sec-
ond generation antipsychotics, concomitant benzodiaze-
pines and antidepressants used by our cohort are listed
in Additional file 1: Table S1. For this cross-sectional
analysis, the medication treatment class, neuropsycho-
logical performance, age, gender, years of education,
time since BD diagnosis, treatment with benzodiazepines
or antidepressants and number previous hospitalizations
were noted in these subjects.
Neuropsychological tests
Neuropsychological tests were administered by trained
research associates under the supervision of licensed cli-
nicians. The test battery was intended to emphasize
known areas affected by BD illness and reported in our
prior work [4, 25]. Five specific tests were selected from
the original test battery to capture areas that seem to be
most sensitive to COMT variants. The California Verbal
Learning Test-II (CVLT-II, [26]) was used a measure of
verbal learning and memory. In this task, five consecu-
tive trials of 16 words are presented and overall learning
across the 5 trials was recorded. There was a short-term
delayed free recall trial after a distractor list and a long-
term delayed free recall trial after 20 min. The Rey-
Osterrieth Complex Figure Test (Rey, [27, 28]) was used
as a measure of visual learning and memory and re-
quired subjects to draw from memory a complex figure
that they previously copied and then to recall from
memory the figure again after 20 min. To assess execu-
tive functioning, the Wisconsin Card Sorting Test
(WCST, [29]), a measure of novel problem solving task,
and the Trail Making Test (Parts A and B: TMT, [30]), a
measure of set-shifting and sequencing, were adminis-
tered. For the WCST, subjects had to sort cards accord-
ing to a sorting strategy that they learned based on
receiving feedback about prior sorts. Number and type
of errors were recorded as well as how many categories
sorted. For the TMT Part A, subjects had to manually
connect dots in order of numbers that were presented in
a spatial array. For the TMT Part B, subjects had to al-
ternate connecting numbers and letters. Total seconds
to complete each task was recorded. To assess cognitive
control (the ability to engage and disengage in response
behaviors), often seen as an element of attention, we
used the Parametric Go/No-Go task (PGNG, [31]), a
computerized continuous performance test that consists
of three separate levels, but only the first level was used
for this study. The first level measures attention and
response time, resulting in two measures of cognitive
control. Subjects respond to a serial stream of letters,
pressing a keyboard as quickly as possible whenever they
see specific letter.
Genotyping
Genotyping was done using the HumanCoreExome-12v1
DNA Analysis BeadChip Kit (Illumina, INC., San Diego,
CA). Samples were genotyped for greater than 240,000
tagSNP markers and more than 240,000 exome markers
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by the University of Michigan DNA Sequencing Core.
DNAs were quantified using the Quant-iT™ PicoGreen®
dsDNA Kit (Invitrogen Corporation, Carlsbad, CA) and
samples were assayed according the Illumina Infinium® HD
Ultra Protocol. BeadChip image data was recorded using
an Illumina iScan Mircroarray Scanner with the Infinium
NXT scan setting. Sample image data were analyzed and
genotypes determined using the Illumina GenomeStudio
(v2011.1) DNA Analysis Software package with Genotyp-
ing Modulue (v1.9.4) using the HumanCoreExome-12v1-
0_B Manifest and HumanCoreExome-12v1-0_B Cluster
file from Illumina. To limit false positives, we conducted a
priori analysis with COMT due to previous associations
with COMT variants and cognition. Two SNPS available
for analysis were COMT rs5993882 and rs165599. Initial
data for rs165599 did not show any association with SGA
use and cognition and therefore, we focused our analysis
on rs5993882.
Statistical analyses
Hardy–Weinberg equilibrium was tested by a Chi Square
analysis. Demographic differences between treatment
groups were examined with a standard t-test or one-way
ANOVA for continuous variables and a chi-square for
nominal variables. We performed linear regressions for
the multiple variable analyses. For the first linear regres-
sion, the cognitive test scores in treatment groups (SGA-
treated vs. non-SGA treated) were compared for the three
COMT rs5993882 genotypes (GG, GT, TT). We adjusted
the model for known predictors that may confound cogni-
tive performance, such as age, years of education, gender,
diagnosis, benzodiazepine or antidepressant concomitant
use, and prior hospitalizations. For tests that were statisti-
cally significant, we additionally ran a follow-up analysis
using chlorpromazine (CPZ) equivalents as a continuous
variable. The second linear regression also was adjusted
for these covariates but included new predictors such as
COMT genotype and an SGA- COMT interaction. In the
second regression model, the GG COMT genotype was
used as the comparator for the combined GT and TT
genotypes.
Due to the number of cognition test scores, we have ad-
justed the significance value for regression model 1 using a
Bonferroni correction for multiple testing (p ≤ 0.0043). For
analysis using CPZ-equivalent doses and regression model
two, we considered a p value of ≤ 0.05 to be significant. All
analyses were conducted in SAS 9.3 (Cary, NC, USA).
Results
SNP and haplotype association
Fifty eight patients were homozygous for the COMT
rs5993882 GG genotype, 120 patients were heterozygous
(GT) and 52 patients were homozygous for the TT geno-
type. No significant deviations from Hardy–Weinberg
equilibrium were observed for the COMT rs5993882 in
the tested population (p > 0.5).
Study population characteristics
Table 1 represents the demographic parameters of our
study population. As cognition can be affected by a
number of factors such as age, years of education, gender,
diagnosis, severity of BD and concomitant medications,
these demographics were used as confounders in our re-
gression models to account for differences between the
different genotypes. Our analysis showed significant inter-
group differences in gender, concomitant benzodiazepine
or antidepressant use, and type of BD diagnosis (see
Table 1) with non-SGA treatment group containing more
females, less concomitant benzodiazepine and antidepres-
sant use and increased BD-II, BD NOS diagnosed subjects.
Mood symptom scores (HAMD, YMRS), recorded at the
same time as cognitive testing, showed no statistical differ-
ences between treatment populations. As SGAs can be
associated with greater severity of BD illness, intergroup
variances between time since BD diagnosis and number of
previous hospitalizations were also noted. The SGA-
treatment group showed a statistically higher number of
hospitalizations and this was adjusted for in our regression
analysis.
Analysis of COMT genotypes and cognition in SGA-
treated BD patients
We initially examined the association of cognitive defi-
cits in SGA-treated subjects stratified by their COMT
rs5993883 genotypes (linear regression 1; Table 2). We
adjusted this model for age, education, gender, type of
BD diagnosis, number of hospitalizations, as well as
treatment with benzodiazepines and antidepressants.
Our model showed that the GG allele genotype was
associated with statistically significant lower scores in
specific cognitive domains, such as verbal memory and
cognitive control, in subjects treated with an SGA com-
pared to those treated with SGA and with a GT and TT
allele. Second generation antipsychotic-treated subjects
homozygous for the GG genotype showed a significantly
worse CVLT-II verbal learning score when compared
to non-SGA treated patients who also carry the GG
genotype (p = 0.0006; β = −10.88; r2 = 0.51). Although there
were no differences between treatment groups for short-
term verbal memory (CVLT-II), long-term delayed verbal
memory was significantly lower in SGA-treated subjects
with the GG genotype (p = 0.0026 β = −3.43; r2 = .28) com-
pared to non-SGA treated subjects with the same geno-
type. The same analysis using CPZ-equivalents found
similar findings noting worse CVLT-II verbal learning (p =
0.009; β = −0.02; r2 = 0.45) and verbal memory (p = 0.016;
β = −0.009; r2 = 0.23) in subjects with GG genotypes and
higher CPZ-equivalent doses. Subjects treated with SGAs
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also exhibited lower cognitive control scores as measured
by the PGNG-Accuracy score (p = 0.004; β = 0.083; r2 =
0.23) compared to those with non-SGA, however, these
results were not significant when considering CPZ-
equivalents (p = 0.1; β = −0.0001; r2 = 0.12) Interestingly,
there were no significant cognitive deficiencies between
treatment groups when stratified for the heterozygous
(GT) or the homozygous minor allele (TT) genotypes.
Table 1 Demographic characteristics
NO-SGAa SGAa p value
N (%) or N (%) or
Mean (SD) Mean (SD)
Gender
Female 119 (69.2) 41(55.4) 0.037
Male 53 (30.8) 33 (44.6)
Years of education in years (SD) 15.4 (2.9) 15.2 (3.2) 0.63
Age in years (SD) 40.3 (12.9) 40 (11.3) 0.83
Time since diagnosis in years (SD) 14.3 (11.7) 13.9 (10.7) 0.75
Previous hospitalizations 113 (65.7) 58 (78.4) 0.047
Medications
Benzodiazepines 28 (16.3) 26 (35.1) 0.001
Antidepressants 48 (27.9) 37 (50.0) 0.0008
Chlorpromazine equivalents NA 210 (787)
Mood symptoms
HAMDb 8.9 (6.6) 8.2 (6) 0.43
YMRSc 3.1 (4.1) 3.2 (3.8) 0.85
Diagnosis
Bipolar I 115 (66.9) 63 (85.1) 0.014
Bipolar II with recurrent depression 34 (19.7) 5 (6.8)
Bipolar NOSd 18 (10.5) 3 (4.0)
Schizoaffective, Bipolar 5 (2.9) 3 (4.0)
COMT rs5993883
GG 44 (25.6) 14 (18.9) 0.5
GT 88 (51.2) 40 (54.1)
TT 40 (23.2) 20 (27.0)
Neuropsychological Tests (SD)
Rey Visual Memory Immediate Recall 21.1 (6.8) 19.1 (6.3) 0.02
Rey Visual Memory Delayed Recall 21.2 (6.5) 19.3 (7.03) 0.043
CVLT-IIe Trials 1–5 Score (Learning) 53.9 (11.1) 48.7 (11.4) 0.0009
CVLT-II Short Delay Recall Score 11.4 (3.4) 10.7 (3.7) 0.18
CVLT-II Long Delay Recall Score 12.1 (3.5) 10.5 (3.7) 0.0008
WCST-f Total Errors 23.2 (21.7) 24.5 (22.3) 0.67
WCST- Perseverative Responses (Percentile) 50 (28.9) 49.9 (31) 0.95
WCST-Categories 5.2 (1.7) 5.1 (1.8) 0.53
TMTg A Time (seconds) 29.6 (10.7) 31.2 (11.6) 0.28
TMT B Time (seconds) 71.5 (29.7) 80.8 (34.9) 0.03
PGNGh Response Time (Level 1) 463.5 (50.8) 467.9 (56.5) 0.5
PGNG Target Accuracy (Level 1) 0.9 (0.1) 0.9 (0.1) 0.10
aSGA atypical antipsychotic, bHAMD the Hamilton rating scale for depression; cYMRS Young mania rating scale, dNOS not otherwise specified, eCVLT-II California
verbal learning test-II, fWCST Wisconsin card sorting test, gTMT trail making test, hPGNG parametric go-no-go test
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Table 2 Effects of SGA on mean cognitive stores stratified by COMT rs5993883 genotype
COMT rs5993883 GG (n = 58) GT (n = 128) TT (n = 52)
No-SGA (STD) SGA (STD) beta p value r2 No-SGA (STD) SGA (STD) beta p value r2 No-SGA (STD) SGA (STD) beta p value r2
Rey Visual Memory Immediate recall 20.9 (6.9) 17.4 (7.2) −4.13 0.09 0.15 20.7 (6.7) 19.2 (6.4) −1.8 0.88 0.22 22.2 (6.9) 20.0 (5.5) −2.2 0.27 0.16
Rey Visual Memory Delayed recall 20.6 (6.9) 17.4 (7.4) −3.96 0.11 0.14 21.0 (6.2) 19.3 (7.4) −0.14 0.91 0.19 22.3 (6.8) 20.6 (6.1) −2.25 0.25 0.23
CVLT-IIa learning score 56.6 (10.1) 45.1 (11.7) 10.88 0.0006 0.51 52.0 (12.2) 49.3 (10.9) −1.77 0.46 0.17 55.2 (8.9) 50.1 (12.0) −2.77 0.32 0.36
CVLT-II short term delayed free recall 11.6 (3.2) 9.8 (4.5) −1.6 0.18 0.15 11.0 (3.4) 10.9 (3.5) −0.12 0.85 0.15 12.0 (3.4) 11.1 (3.8) −0.68 0.54 0.12
CVLT-II long-term delayed free recall 12.9 (3.1) 9.4 (3.2) −3.43 0.0026 0.28 11.4 (3.7) 10.7 (3.1) −0.22 0.75 0.18 12.7 (3.1) 11.0 (3.1) −0.92 0.29 0.19
WCSTb total errors 24.4 (23.5) 27.5 (19.1) 9.3 0.21 0.21 25.1 (22.9) 23.7 (22.9) −1.17 0.7 0.19 17.7 (15.9) 24.1 (24.2) 6.7 0.23 0.3
WCST perseverative responses 14.3 (15.4) 15.4 (14.6) 4.98 0.33 0.16 15.4 (16.3) 14.1 (16.4) −1.61 0.62 0.18 9.5 (9.2) 14.5 (17.3) 5.27 0.17 0.25
WCST number of categories 5.2 (1.7) 5.2 (1.3) −0.4 0.47 0.12 5.1 (1.7) 5.1 (1.9) 0.07 0.83 0.16 5.5 (1.4) 5.0 (1.9) −0.52 26 0.28
TMT Part A Time (sec) 30.5 (13.3) 34.2 (10.9) 3.73 0.39 0.15 29.6 (9.9) 30.5 (11.9) 0.042 0.98 0.15 28.4 (9.3) 30.5 (11.5) 1.3 0.62 0.4
TMT Part B Time (sec) 75.9 (36.5) 82.1 (30.6) 2.44 0.83 0.16 72.5 (27.4) 80.6 (36.4) 3.5 0.55 0.25 65.2 (25.6) 80.5 (36.5) 10.6 0.2 0.35
PGNGc response time (msec) 468.2 (47.2) 492.2 (61.6) 18.6 0.33 0.19 467.5 (53.4) 463.8 (59.5) −1.79 0.55 0.2 451.2 (46.8) 459.6 (43.5) 11.3 0.38 0.22
PGNG Target accuracy (%) 0.96 (0.05) 0.88 (0.11) 0.083 0.004 0.23 0.95 (0.07) 0.95 (0.06) 0.002 0.86 0.17 0.98 (0.05) 0.96 (0.07) −0.02 0.23 0.12
This model was adjusted for age, education, gender, diagnosis, prior hospitalizations, benzodiazepines and antidepressant use
aCVLT-II California verbal learning test-II
bWCST Wisconsin card sorting test












Interaction of COMT rs5993883 genotype GG with SGAs
on verbal cognition and impulsivity
Due the observation that these SGA-associated cognitive
deficits were only observed in the GG strata, we com-
bined the GT and TT groups and used their scores as a
comparator to the GG genotype to measure an inter-
action between genotype and verbal learning, verbal
memory and cognitive control in SGA and non-SGA
treatment populations (linear regression 2; Table 3). Also
included in this regression model was the contribution
of the genotype itself without the SGA-interaction,
which combined the GT and TT populations and com-
pared it to the GG genotype. Interestingly, the COMT
genotype itself was a significant parameter in this model.
We also observed a significant interaction between SGA
treatment and COMT genotype on verbal learning (p =
0.028; β = 7.95; r2 = 0.25) and verbal long-term delayed
memory (p = 0.026 β = 2.38; r2 = 0.21). We also found a
significant interaction between genotype and SGA-
treatment when examining deficits in cognitive control.
(p = 0.0005; β = 0.083; r2 = 0.15).
Discussion
In this work, we found an association between the GG
genotype of COMT rs5993883 and SGA-treatment with
these individuals with BD showing poorer cognitive
performance than those with the GT or TT genotypes.
Specifically, we observed significantly lower scores in
areas of verbal cognition and cognitive control in this
treatment population, indicating that individuals with
BD who receive SGA treatment and have the GG geno-
type are at risk for greater difficulties in learning and
remembering verbal or auditory information and they
are less accurate when required to engage and disengage
their attention to stimuli. Overall, they may be less effi-
cient with learning, memory, and attentional capacity.
Although the results of the PGNG Target Accuracy test
was not significant when considering CPZ-equivalents,
this may be due to non-dose dependent pharmacologic
effects. This cohort also exhibited a significant inter-
action between the SGA-class of medication and COMT
genotype in the same cognitive domains.
Neuropsychological studies of patients with brain in-
juries and neuroimaging work has indicated that dopa-
mine action in the prefrontal cortex, dorsal striatum and
hippocampus is critical for high level cognitive function-
ing [32–34]. O-methylation by COMT is one of the
major degradative pathways for catecholamine neuro-
transmitters such as dopamine [15]. Consistent with its
role in catecholamine metabolism in the prefrontal cor-
tex, variation in this gene has been linked with decreased
cognitive function in BD, schizophrenia and in healthy
controls [14, 16, 35]. The most widely studied COMT
variant allele is the COMT Val108/158Met polymorphism
rs4680. This variant affects the stability and enzymatic
activity of catechol-O-methyltransferase, which alters the
enzyme's ability to methylate catecholamines in the pre-
frontal cortex [36–38]. In previous work, Val allele load
has been associated with detrimental effects in cognition
for schizophrenia subjects and has also been linked to a
further decrease in cognition in BD patients treated with
SGAs [9].
The polymorphism COMT rs5993883 is located in
intron 1 of the COMT gene and is not strongly linked to
the rs4680 polymorphism (Distance = 13633 base pairs;
r2 = .327; d’ = 0.654; www.broadinstitute.org/mpg/snap/).
In previous work, this mutation has been weakly associ-
ated with creativity, cocaine induced paranoia and modu-
lation of certain personality traits including suicidal
behavior [15, 39, 40]. Additionally, the rs5993883 G allele
has been associated with cognitive manic symptoms in BD
patients [41]. Intron variants are not in the protein-coding
region of a gene but can generally affect function by alter-
ing processes such as transcription or alternative splicing,
in which several splice variants have been noted for
COMT [42–44]. Although no structural or transcriptional
changes in function have been defined for COMT
rs5993883, it’s possible that this variant could affect these
types of processes.
Impairments in cognition are noted as being robustly
evident in the schizophrenia literature but have also
been noted in BD patients, although to a lesser degree.
When compared to healthy controls, euthymic BD pa-
tients show deficiency in executive functioning, verbal
memory, psychomotor speed and sustained attention
Table 3 Interaction between SGA and COMT polymorphism rs5993883 on cognition in bipolar patients (using GG genotype as
a reference)
Cognitive parameter Verbal attentiona (r2 = 0.25) Verbal delayed recalla (r2 = 0.21) Cognitive controlb (r2 = 0.15)
beta p value beta p value beta p value
SGA −10.03 0.0019 −3.03 0.0022 −0.08 <0.0001
COMT genotype −4.65 0.013 −1.43 0.013 −0.007 0.54
Main Interaction 7.95 0.028 2.38 0.026 0.083 0.0005
This model was adjusted for age, education, gender, diagnosis, prior hospitalizations, benzodiazepines and antidepressant use
aAge, education and gender were also significant parameters in this model
bAge was also a significant parameter in this model
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[45]. It has also been observed that in first degree rela-
tives, the cognitive domains of executive functioning and
verbal memory are significantly different from healthy
controls, which suggests these domains are bipolar
endophenotypes reflecting a genetic link to BD [46].
Impaired inhibitory behavioral control in manic and
euthymic BD subjects is a specific cognitive impairment
that has also been described as distinct from the universal
neuropsychological deficiency linked to other psychotic
disorders [47, 48]. The overall cause of neurocognitive
deficits in BD patients is likely multifactorial including
genetic, medication and symptom considerations. Al-
though deficiencies in verbal memory have been described
in the BD population, we have observed further dec-
rements in this domain due to an interaction between
SGA-treatment and the GG genotype of the COMT
rs5993883 variant. We also described a relationship
between COMT rs5993883 and SGA-treatment on
deficiencies in cognitive control as measured by a
continuous performance test (PGNG).
Second generation antipsychotics have a role in the
management of not only BD-associated mania but are
also effective in BP-associated depression. Although the
mechanistic basis for the efficacy of SGAs in mood dis-
orders is not completely understood, the ability to block
D2 and serotonin 5HT2A receptors are likely to contrib-
ute. Dopamine dysregulation is thought have a role in
the psychopathology of BD [49]. However, in contrast to
the cognitive improvement observed in SGA-treated
schizophrenia patients, SGAs use within the BD popula-
tion has been associated with lower cognitive function-
ing. As a further complication for cognition in this
group, our work and others have shown that treatment
with SGAs may confer further decrements in cognition
if the subject caries COMT variants [9]. In this report,
we observe that a well-characterized large group of BD
subjects show significantly lower cognitive performance
in specific domains of verbal cognition and cognitive
control that are associated with an SGA-treatment inter-
action with a GG genotype of COMT rs5993883.
Study limitations
As this study was cross-sectional in design, we miss look-
ing longitudinally at cognitive measures in APP-treated
subjects over time. In the future, as we accumulate more
data in the Prechter longitudinal cohort, a longitudinal
analytic approach will be informative. Additionally, we
know that members of the SGA-class are not identical in
either the mechanism of action or side effects. In this
study, we did not distinguish between specific SGA-
medications but this may be warranted in future work.
Greater severity of illness is associated with SGA treat-
ment in the BD population, which can also result in
reduced cognitive functioning. In an attempt to address
this disparity, we adjusted our model for prior hospitali-
zations, as an indicator of disease severity, which showed
a statistically significant increase in the SGA-treated
population. However, it may also be important to consider
other factors such as medication switching or chlorpro-
mazine equivalents for SGA use to assess severity of
illness. And finally, we also had a significantly under
representation of the BD-II and schizoaffective BD type
diagnoses when compared to subjects with a BD-I diagno-
sis. There may be differences in the effect of COMT
variant alleles and interactions with SGA-treatment in the
less-represented diagnosis in our subject cohort. As we
accrue more subjects, this analysis may be possible using
the Prechter cohort.
Conclusions
This investigation contributes to work illustrating links
between cognition, SGA-treatment and COMT in BD
subjects. Our analysis highlights significant associations
between decreased verbal-cognition and cognitive control
in SGA-treated subjects carrying the COMT rs5993883
GG-genotype. Prospective studies are needed to assess the
clinical importance of these findings.
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